Site Directed Mutation Of Ctx Operon In Vcusm2, Vibrio Cholerae Vaccine Candidate Strain: Towards

The Development Of A Vaccine For Cholera 

[RA644.C3 C454 2008 F rb]. by CHAN, MELISSA LI ANN
   
SITE DIRECTED MUTATION OF ctx OPERON IN VCUSM2,  
Vibrio cholerae VACCINE CANDIDATE STRAIN: TOWARDS 
THE DEVELOPMENT OF A VACCINE FOR CHOLERA 
 
 
 
 
 
 
by 
 
 
 
 
 
 
MELISSA CHAN LI ANN 
 
 
  
 
 
 
 
 
Thesis submitted in fulfilment  
of the requirements for the degree of 
Masters of Science 
 
 
 
 
 
 
July 2008 
 ii 
Acknowledgements 
 
This research endeavor has been a tiring yet fulfilling journey of the wonders of science and 
the acknowledgement that the Creator of our universe is immensely powerful, sovereign, 
interested and very much involved in even the smallest detail of life. Should the discoveries 
of this study deserve any praise, may it all be to God in the highest! 
 
My gratitude goes to my supervisor, Dr. M. Ravichandran, and his wife, Dr. P. Lalitha for 
their continuous support, encouragement, and generosity with his time, wisdom and 
guidance, not only in the academic field but also in my personal life. Many thanks also to 
Prof. Dr. Zainul F. Zainuddin, my co-supervisor, who continues to motivate and open doors 
of opportunity for people like me into the world of scientific research.  
 
I have also been privileged to work alongside amazing people for the many years in the lab. 
Lim, Jo-Anne, Yean Yean, Kuru, Nik, Kak Linda, and Atif and many others have taught me, 
scolded me, worked with me and laughed with me.  
 
To Su Yin, you are more than a labmate, more than a friend. I’ve been so blessed to have 
you as my companion throughout the years! It has been an honor and joy to know you and 
work alongside you. 
 
I would also like to acknowledge Dr Fando and CNIC; INFORMM; and USM’s Pasca 
Siswazah scheme for the scholarship I received.  
 
Finally, I wish to thank my family for believing in me and for releasing me to do this. 
 
- Thank you - 
 
This work was supported by grant from Ministry of Science, Technology and the 
Environment, Government of Malaysia (IRPA RM7). 
 
 
 
 
 
 iii
TABLE OF CONTENTS 
 
 
 
Acknowledgements ........................................................................................................................ii 
 
Table of Contents ..........................................................................................................................iii 
 
List of Tables .................................................................................................................................vi 
 
List of Figures...............................................................................................................................vii 
 
List of abbreviations .....................................................................................................................ix 
 
Abstrak ...........................................................................................................................................x 
 
Abstract..........................................................................................................................................xi 
 
Chapter 1: Introduction ................................................................................................................1 
1.1 Cholera .............................................................................................................................1 
1.2 Epidemiological data and statistics ..................................................................................1 
1.3 Pathophysiology...............................................................................................................2 
1.4 Prevention & vaccines & cost ..........................................................................................3 
1.5 Strains...............................................................................................................................5 
1.5.1 Serogroup ............................................................................................................5 
1.5.2 Serotype...............................................................................................................6 
1.5.3 Biotype ................................................................................................................6 
1.6 CTXΦ Phage ....................................................................................................................7 
1.7 Toxins & Proteins ............................................................................................................8 
1.8 VCUSM2........................................................................................................................10 
1.9 Objectives.......................................................................................................................11 
 
Chapter 2: Materials and Methods ............................................................................................12 
2.1 Experimental overview ..................................................................................................12 
2.2 Reagents, chemicals, kits ...............................................................................................13 
2.2.1 Culture media ....................................................................................................13 
2.2.1.1 Luria Bertani (LB) agar ........................................................................13 
2.2.1.2 Luria Bertani (LB) broth.......................................................................13 
2.2.1.3 Modified LB agar without NaCl and with 10% sucrose.......................14 
2.2.1.4 Modified LB broth without NaCl and with 10% sucrose .....................14 
2.2.1.5 TCBS Agar ...........................................................................................15 
2.2.1.6 Addition of antibiotics/ supplements to the agar based media .............15 
2.2.2 General buffers, stock solutions, antibiotics......................................................16 
2.2.2.1 δ-Aminolevulinic Acid 40 mg /ml........................................................16 
2.2.2.2 Ampicillin 100 mg/ml ..........................................................................16 
2.2.2.3 Calcium chloride 100 mM....................................................................16 
2.2.2.4 Carbonate buffer 60 mM pH 9.6...........................................................17 
2.2.2.5 Cholera toxin (0.5 µg /ml) ....................................................................17 
2.2.2.6 Ethanol 70% .........................................................................................17 
2.2.2.7 EDTA 0.5 M.........................................................................................17 
2.2.2.8 Ethidium bromide 10 mg /ml................................................................18 
2.2.2.9 Gel loading dye 6X...............................................................................18 
2.2.2.10 Glycerol 80%......................................................................................18 
 iv 
2.2.2.11 Hydrochloric Acid 1N ........................................................................19 
2.2.2.12 Kanamycin sulfate 50 mg /ml.............................................................19 
2.2.2.13 Magnesium chloride 100 mM.............................................................19 
2.2.2.14 Normal saline (0.9% NaCl) ................................................................19 
2.2.2.15 Phosphate Buffered Saline (PBS) 10 X..............................................20 
2.2.2.16 Phosphate Buffered Saline-Tween 20 ................................................20 
2.2.2.17 Polymyxin B sulfate 0.75 mg /ml (4500 units)...................................20 
2.2.2.18 Sodium bicarbonate 60 mM................................................................21 
2.2.2.19 Sodium carbonate 60 mM...................................................................21 
2.2.2.20 Sodium hydroxide 10M......................................................................21 
2.2.2.21 Sodium hydroxide 1M........................................................................21 
2.2.2.22 Skimmed milk 5% ..............................................................................22 
2.2.2.23 Tris Acetic Acid EDTA (TAE) 50X...................................................22 
2.2.2.24 Tris Acetic Acid EDTA (TAE) 1X.....................................................22 
2.2.2.25 TypeIII Ganglioside (10 µg /ml) ........................................................22 
2.2.3 Bacterial species and strains..............................................................................23 
2.2.3.1 E. coli BW 20767- λ pir........................................................................23 
2.2.3.2 E .coli TOP10 .......................................................................................23 
2.2.3.3 V. cholerae O139 Bengal......................................................................23 
2.2.3.4 VCUSM2..............................................................................................23 
2.2.4 Plasmids.............................................................................................................24 
2.2.4.1 pTZ57R.................................................................................................24 
2.2.4.2 pWM91.................................................................................................24 
2.2.5 Animals .............................................................................................................24 
2.3 Methods..........................................................................................................................25 
2.3.1 Bacterial strains and culture conditions.............................................................25 
2.3.1.1 Medium term storage of bacterial strains as glycerol stock..................25 
2.3.1.2 Recovery of bacteria from glycerol stock.............................................26 
2.3.1.3 Long term storage of bacterial strains as lyophilized stock..................26 
2.3.1.4 Recovery of bacteria from lyophilized stock........................................26 
2.3.2 Cloning and mutagenesis...................................................................................28 
2.3.2.1 PCR.......................................................................................................28 
2.3.2.1.1 Primer designing...................................................................28 
2.3.2.1.2 Preparation for bacterial lysate for PCR...............................31 
2.3.2.1.3 PCR amplification ................................................................31 
2.3.2.1.4 Inverse PCR..........................................................................32 
2.3.2.2 Site-directed mutagenesis .....................................................................32 
2.3.2.2.1 Designing mutagenic primers ...............................................32 
2.3.2.2.2 Site directed mutagenesis master mix...................................33 
2.3.2.2.3  Temperature cycling............................................................34 
2.3.2.2.4  Plasmid Digestion................................................................34 
2.3.2.3 Ligation.................................................................................................35 
2.3.2.4 Transformation .....................................................................................36 
2.3.2.4.1 Competent cell preparation...................................................36 
2.3.2.4.2 Transformation by Calcium Chloride method......................36 
2.3.2.5 Restriction enzyme ...............................................................................37 
2.3.2.5.1 FseI .......................................................................................37 
2.3.2.5.2 SmaI......................................................................................37 
2.3.2.5.3 SacI & SalI............................................................................37 
2.3.2.5.4 SacI & SmaI..........................................................................37 
2.3.2.5.5 SacI, SmaI & BglI.................................................................38 
2.3.2.6 Blunting DNA strands ..........................................................................38 
2.3.2.7 Kinasing................................................................................................38 
2.3.2.9 Electrophoresis .....................................................................................39 
2.3.3 Conjugation .......................................................................................................40 
 v 
2.3.3.1 Preparation of donor cells.....................................................................40 
2.3.3.2 Preparation of recipient cells ................................................................40 
2.3.3.3 Conjugative mating...............................................................................41 
2.3.3.4 Phenotypic screening............................................................................41 
2.3.3.5 Genotypic screening .............................................................................42 
2.3.4 Sucrose selection ...............................................................................................42 
2.3.4.1 Phenotypic screening............................................................................42 
2.3.4.2 Genotypic screening .............................................................................43 
2.3.4.3 Serotyping.............................................................................................44 
2.3.5 Cholera Toxin ELISA .......................................................................................44 
2.3.6 Ileal Loop Ligation............................................................................................45 
2.3.7 Infant Mouse colonization.................................................................................45 
 
Chapter 3: Results........................................................................................................................46 
3.1 Plasmid construction ......................................................................................................48 
3.1.1 pTZctxOp ..........................................................................................................49 
3.1.2 pTZctxOp-MD...................................................................................................53 
3.1.3 pcODmA ...........................................................................................................57 
3.1.3a pWM-coDmA ........................................................................................64 
3.1.4 pcoDmAKan......................................................................................................68 
3.1.4a pWM-coDmAKan .................................................................................72 
3.1.5 pcoDmA ∆Kan ..................................................................................................75 
3.1.5a pWM-cODmA ∆Kan .............................................................................79 
3.2 Sequencing .....................................................................................................................83 
3.3 Conjugation....................................................................................................................84 
3.4 Serotyping ......................................................................................................................95 
3.5 Cholera Toxin ELISA ....................................................................................................95 
3.6 Rabbit ileal loop .............................................................................................................96 
3.7 Infant mouse colonization ..............................................................................................97 
 
Chapter 4: Discussion ..................................................................................................................98 
 
References...................................................................................................................................103 
 
Appendices..................................................................................................................................107 
 
 vi 
List of Tables 
 
 
 
Table 2.1: Bacterial strains and culture conditions ..................................................... 25 
 
Table 2.2: Primers used in this study, their sequences and functions......................... 29 
 
Table 2.3: Primers used for mutagenesis and screening of mutations, their 
sequences and function in this study ............................................................................ 30 
 
Table 2.4: Composition of a standard PCR master mix for a 20 µl reaction.............. 31 
 
Table 2.5: Typical PCR cycling conditions used in this study..................................... 32 
 
Table 2.6: Mutagenic primer sequences and %GC..................................................... 33 
 
Table 2.7: PCR program for site directed mutagenesis .............................................. 34 
 
Table 2.8: Culture plates used in phenotypic screening of merodiploids and V. 
cholerae mutants ........................................................................................................... 43 
 
Table 3.1: Constructed plasmids, inserts and description of the inserted genes ........ 48 
 
Table 3.2: Fluid accumulation results from rabbit ileal loop ligation experiment ..... 96 
 
Table 3.3: Inoculum size and recovery of V. cholerae strains in infant mouse 
colonization experiments .............................................................................................. 97 
 
 vii 
List of Figures 
 
 
Figure 1: Experimental overview ................................................................................. 12 
 
Figure 2: Schematic representation of conjugation and allele replacement 
towards the construction of VCUSM14 ....................................................................... 47 
 
Figure 3: Amplification of ctx operon .......................................................................... 49 
 
Figure 4: PCR screening of ctxAB in pTZ-ctxOp........................................................ 51 
 
Figure 5: Diagram of pTZ-ctxOp................................................................................. 52 
 
Figure 6: Inverse PCR for the deletion of ace and zot ................................................. 54 
 
Figure 7: PCR screening for deletion of ace and zot in mutant plasmids ................... 55 
 
Figure 8: Restriction enzyme analysis of pTZctxOp-MD............................................ 56 
 
Figure 9: Site directed mutagenesis of 7th amino acid codon ...................................... 58 
 
Figure 10: PCR screening for mutated 7th amino acid codon using mutant 
specific primer, MctxA7MS-F...................................................................................... 59 
 
Figure 11: PCR screening of mutated 7th amino acid with wild type primer, 
MctxA7WS-F ................................................................................................................ 60 
 
Figure 12: Site directed mutagenesis of 112th amino acid codon................................. 61 
 
Figure 13: PCR screening of 112th amino acid codon mutation with mutant 
specific (MctxA112MS-F) and wild type specific (MctxA112WS-F) primers ............ 62 
 
Figure 14: Diagram of pcODmA.................................................................................. 63 
 
Figure 15: Restriction of pcODmA with SacI and SalI ............................................... 65 
 
Figure 16: PCR screening for pWM-cODmA by amplifying ctxA ............................. 66 
 
Figure 17: Diagram of pWM-cODmA ......................................................................... 67 
 
Figure 18: Restriction enzyme analysis of pcODmAKan and pcODmA to 
compare insert size........................................................................................................ 69 
 
Figure 19: Restriction of pcODmAKan to remove insert from plasmid for 
subcloning purposes...................................................................................................... 70 
 
Figure 20: Diagram of pcODmAKan........................................................................... 71 
 
 viii
Figure 21: PCR screening of pwm-coDmAKan........................................................... 73 
 
Figure 22: Diagram of pWM-cODmAKan .................................................................. 74 
 
Figure 23: Inverse PCR of pcODmAKan to truncate aphA gene ............................... 76 
 
Figure 24: PCR screening of pcODmA ∆Kan by PCR................................................ 77 
 
Figure 25: Diagram of pcODmA ∆Kan........................................................................ 78 
 
Figure 26: Restriction of pcODmA ∆Kan using SacI, SmaI and BglI ........................ 80 
 
Figure 27: PCR screening for pWMcODmA ∆Kan .................................................... 81 
 
Figure 28: Diagram of pWM--cODmA ∆Kan ............................................................. 82 
 
Figure 29: PCR screening for merodiploid for ctx operon.......................................... 85 
 
Figure 30: PCR screening of ace and zot genes in VCUSM11..................................... 86 
 
Figure 31: PCR screening merodiploid (potential VCUSM12) for sacB gene............ 87 
 
Figure 32: PCR screening for the loss of ace gene in VCUSM12................................ 88 
 
Figure 33: PCR screening of merodiplod (potential VCUSM13) for sacB gene......... 89 
 
Figure 34: PCR screening of possible VCUSM13 for deletion of aphA gene.............. 90 
 
Figure 35: PCR screening of merodiploids (potential VCUSM14) for sacB gene ...... 91 
 
Figure 36: PCR screening for aphA and truncated aphA in VCUSM14 .................... 92 
 
Figure 37: PCR screening for mutated 7th amino acid in VCUMS14 ......................... 93 
 
Figure 38: PCR screening for mutated 112th amino acid codon in VCUSM14 .......... 94 
 
 ix 
List of abbreviations 
 
 
 
∆Kan   mutated aphA gene 
10X      10 times 
ALA    δ-aminolevulinic acid 
bp      base pair 
ChrI    chromosome 1 
CNIC    Centro Nacional de Investigaciones Científicas, Cuba 
 
CT   cholera toxin 
CTA    cholera toxin subunit A 
CTB    cholera toxin subunit B 
CTXΦ   cholera toxin phi phage 
 
 x 
Mutasi tertumpu tapak operon ctx dalam VCUSM2, calon vaksin 
Vibrio cholerae: ke arah pembangunan vaksin kolera 
 
ABSTRAK 
 
Kolera ialah penyakit cirit-birit akut dan dahsyat yang disebabkan oleh jangkitan bakteria 
Vibrio cholerae O1 dan O139. Ia merupakan penyakit endemik di negara-negara yang tidak 
mempunyai sumber air yang bersih mahupun sistem kumbahan yang baik. Jumlah kes akibat 
kolera dilaporkan semakin meningkat. Vaksin yang memberi perlindungan terhadap 
jangkitan V. cholerae O139 belum wujud lagi. Objektif kajian ini adalah untuk 
membangunkan vaksin O139 yang telah dilemahkan melalui mutasi operon ctx dalam 
VCUSM2. Mutasi ini akan menjadikan VCUSM2 tidak toksik tetapi mengekalkan 
keupayaan perangsangan sistem imun badan. VCUSM2, adalah mutan hemA, strain O139, 
yang memerlukan bekalan ALA luaran dan mempunyai dua salinan operon ctx. Operon ini 
diklonkan dalam pTZ57R, ace dan zot dilupuskan melalui PCR songsang, dan asid amino 
ke-7 dan ke-112 subunit A toksin kolera dimutasikan. VCUSM14 dihasilkan melalui siri 
eksperimen konjugasi VCUSM2 dengan BW20767-λpir yang membawa pWM91 yang 
mengandungi gen-gen tertentu, diikuti pemilihan sukrosa. VCUSM14 tidak mengakibatkan 
cecair berkumpul dalam kajian model usus arnab (‘rabbit ileal loop model’) tetapi 
mengkolonikan usus anak mencit (‘infant mouse’) dengan lemah. Molekul toksin kolera 
yang dihasilkan berjaya dikenalpasti melalui ujian CT-ELISA dengan menggunakan antibodi 
poliklonal. VCUSM14 mempunyai potensi dibangunkan sebagai calon vaksin sekiranya 
keupayaan mengkolonisasikan usus berjaya ditingkatkan melalui pengembalian gen hemA 
yang sempurna ke dalamnya. 
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Site Directed Mutation of ctx operon in VCUSM2, Vibrio cholerae 
vaccine candidate strain:  
Towards the development of a vaccine for cholera 
 
ABSTRACT 
 
Cholera is an acute diarrheal disease caused by Vibrio cholerae O1 and O139. It affects 
countries with scarce clean water supplies and poor sanitation systems. Reported cases and 
mortality rates are increasing. No vaccines are available that confers protection against the 
O139 serotype. This study aims to create an attenuated O139 vaccine strain by mutating the 
ctx operon in VCUSM2 through site-directed mutagenesis, rendering it non-toxigenic but 
retaining its immunogenicity. VCUSM2 is a hemA mutated, ALA auxotrophic O139 strain 
with two copies of ctx operon in tandem. The operon was cloned into pTZ57R, ace and zot 
genes were deleted by inverse PCR and the cholera toxin A subunit was mutated at the 7th 
(arginine to lysine, R7K) and 112th (glutamate to glutamine, E112Q) amino acid positions. 
VCUSM14 was obtained through a series of conjugation with BW20767-λpir E. coli 
harboring pWM91 carrying respective inserts, and sucrose selection. VCUSM14 does not 
cause fluid accumulation in rabbit ileal loop model and is a poor colonizer in the infant 
mouse model. CT-ELISA showed that it produces toxin molecules recognizable by 
polyclonal anti-CT antibodies. This strain shows potential for vaccine development once 
colonization abilities are improved through reinsertion of the hemA gene. 
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Chapter 1: Introduction 
 
1.1 Cholera 
Cholera is an acute watery diarrheal disease caused by toxigenic strains of Vibiro cholerae, a 
Gram negative bacillus. The disease is characterized by rice watery stool, vomiting, 
dehydration and in its extreme form cholera gravis, hypovolemic shock and death. It is a 
disease that mainly affects the poor, in countries where clean water and sanitation systems 
are not readily available.  
 
Historically, there have been 7 recorded pandemics of the disease. The first 6 pandemics 
were caused by the classical biotype of O1 V. cholerae. Although strains of the El Tor 
biotype were known to cause sporadic infections, it was only in 1961 that this strain emerged 
to cause the 7th pandemic. 
 
In 1992, a new strain of V.  cholerae was discovered to be the etiologic agent for epidemic 
outbreaks of cholera in India and Bangladesh. As it did not agglutinate in V. cholerae O1 
antiserum or in any of the 137 non-O1 serogroup antisera, this strain was designated the 
name O139, a new serogroup of V. cholerae. V. cholerae O139 is also known as V. cholerae 
Bengal. The concern with regards to the Bengal strain is that it seems highly capable of 
being the etiologic agent for an 8th cholera pandemic.  
 
1.2 Epidemiological data and statistics 
The number of cholera cases reported in 2005 has increased 30% compared to the number of 
cases reported in 2004. In 2005, there were 131,943 cases, with 2272 deaths reported, 
representing a 30% increase compared to the numbers in 2004 (WHO 2006). 
 
 2 
Interestingly, despite major natural disasters such as Hurricane Katrina and the tsunami, 
almost no cholera cases were reported from these affected areas with only 4 cases being 
reported in the United States being linked to Hurricane Katrina (WHO 2006).  
 
Officially notified cases in Asia showed an 18% increase in 2005, with a total of 6824 cases 
and 37 deaths in 9 Asian countries. The Indian continent reported 46% of all cases reported 
in Asia. Indonesia reported 20% of the total cases in Asia and 19 deaths. However, none of 
these cases reported were from the region affected by the tsunami in 2004 (WHO 2006).  
 
Cholera cases are much under reported because of the affect it may have on the tourism 
industry of a country. Although many cases meet the WHO case definition of cholera, they 
are reported as acute watery diarrhea and thus does not describe the actual incidence of this 
disease. In Afghanistan alone, 150,000 cases of acute watery diarrhea were reported in 26 
provinces that, according to WHO case definition, are cholera (WHO 2006).  
 
Information with regards to infection with Vibrio cholerae O139 was only available from 
China where 35% of the laboratory confirmed cases of cholera were attributed to be by the 
O139 strain (WHO 2006). 
 
1.3 Pathophysiology 
Cholera results from the ingestion of pathogenic Vibrio cholerae, usually from a 
contaminated food or water source. The incubation period for the organism varies from 12 to 
72 hours, depending on the size of the inoculum and also the susceptibility of the individual 
(Cash et al., 1974).  
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V. cholerae is highly acid labile and most of the organism would be killed in the acidic 
environment of the gastric pouch. Thus, a relatively large inoculum size (106-108) compared 
to other enteric pathogens is required to establish infection.  
 
Individual susceptibility revolves around the pH of the stomach, where the infectious dose is 
lower and the risk of illness is higher in persons who are hypochlorhydric (Wachsmuth IK, 
1994). In one study, volunteers who were administered sodium bicarbonate to neutralize the 
gastric acid showed that the required infectious dose was much lower than in a normal 
individual. A study with heavy cannabis users reported increased risk of developing diarrhea 
following ingestion of V. cholerae O1 compared with persons who did not smoke cannabis 
or who smoked cannabis less frequently. This finding may explain the patterns of infection 
in the Ganges delta, where cannabis use is common in parts of the population (Wachsmuth 
IK, 1994).  
 
Vibrio cholerae colonizes the epithelial cells of the intestines but does not invade nor alter 
the structure of these cells (Wachsmuth IK, 1994). Once the organism successfully colonizes 
the intestines, the production of cholera toxin leads to the increase of chloride and 
bicarbonate secretion into the intestinal lumen. At the same time, there is a decrease in 
villous absorption of sodium chloride. This causes intracellular fluid to be secreted into the 
intestinal lumen and subsequently leads to the acute diarrhea symptoms characteristic of 
cholera. 
 
1.4 Prevention & vaccines & cost 
Extensive and in depth studies of V. cholerae, its genes, their functions and the proteins they 
code for have been carried out and are still on-going. Yet many people still die of cholera 
yearly (WHO 2006). The long term solution for the problem is to provide safe and clean 
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drinking water and to establish good sanitation systems in communities where cholera is 
endemic. The short term solution would be, and is, to develop a safe, immunogenic, 
affordable vaccine to be administered to the masses in countries where clean water and 
sanitation are not readily available. 
 
However, these countries often do not have the resources to fund mass health campaigns, 
what more to purchase readily available cholera vaccines for a large scale vaccination 
program. Hence, there is a need for a vaccine to be made available to these nations at the 
lowest possible cost. Currently, apart from being too expensive for mass vaccination, the 
available cholera vaccines do not confer long term immunity (Trach et al., 1997, WHO 2004) 
and do not produce convincing protection in differing communities (Richie et al., 2000, 
WHO 2004).  
 
Studies have shown that patients who experience cholera exhibit long term immunity 
towards reinfection (Wachsmuth IK, 1994). This would mean that to produce a long term 
immune affect, the ideal vaccine would need to mimic a true infection. Thus, an attenuated 
live oral vaccine would perhaps offer better protection as compared to whole killed vaccines.  
 
Currently, available vaccines and candidate strains which are mostly of the O1 serogroup 
(Cryz et al., 1995, Fontana et al., 2000, Garcia et al., 2005, Liang et al., 2003, Qadri et al., 
2006, Thungapathra et al., 1999, Yu et al., 2005) do not protect against O139 infection 
(Albert et al., 1994a, Qadri et al., 1997). CVD 103-HgR is an O1 classical Inaba strain that 
has 94% of the ctxA gene absent (Ketley et al., 1993) and is now a commercially available 
vaccine that does not claim to protect against O139 infection (Albert et al., 1994a, Albert et 
al., 1994b).  
 
IEM101 is an attenuated strain that was found to be naturally deficient of the ctxAB gene 
(Liu et al., 1995). Without this gene, the bacteria lacks toxigenicity and does not cause fluid 
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accumulation. However, often efforts to develop a cholera vaccine would seek to make 
available the B subunit in the formulation (Liang et al., 2003, Svennerholm et al., 1984, Sack 
et al., 1997, Ketley et al., 1993, Waldor and Mekalanos, 1994). Hence, IEM108 was 
developed from IEM101 with the insertion of the ctxB gene (Liang et al., 2003). Other O1 
serogroup vaccine strains include the Cuban 638 strain, Peru-15, and Texas Star-SR 
 
Upon discovery that current O1 based vaccines do not help in protecting against O139 
infections, research groups have increased efforts to develop live attenuated O139 strains 
that may be used as vaccines. One such example is Ledon et. al. with the construction of 
thyA and hap mutants from SG-25-1a, a spontaneous ∆CTXΦ mutant O139 strain (Ledon et 
al., 2003). 
 
Coster et. al. describe the construction and evaluation of Bengal-15 (Coster et al., 1995). The 
strain is a stable spontaneous non-motile derivative of Bengal-3, which is absent for the CTX 
element but has been inserted with a construct that encodes for ctxB. 
 
The strain in which this study is involved and interested in is VCUSM2, a hemA mutant 
O139 strain constructed by Ravichandran et. al. (Ravichandran et al., 2006). Further 
description of this strain can be found in 1.8 of this chapter.  
 
1.5 Strains 
1.5.1 Serogroup 
Different O antigens differentiate the serogroups of Vibrios. Currently, more than 139 
different O antigens of V. cholerae have been identified. These O antigens are thermostable 
polysaccharides that are part of the cell wall lipopolysaccharide (LPS) (Wachsmuth IK, 
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1994). The serogroups of V. cholerae can not be chemically identified but are determined by 
respective antisera.  
  
However, only the V. cholerae carrying O1 and O139 antigens are associated with epidemics. 
The remaining serogroups are collectively known as non-O1, non-O139 strains. These 
strains may not be significant as etiologic agents of epidemics but might cause sporadic 
diarrhea, gastroenteritis and occasionally extraintestinal infection such as wound infections 
and acute sepsis. This is observed in people with liver disease or immunosuppression 
(Ramamurthy et al., 1993). 
 
1.5.2 Serotype 
On the basis of variation in antigenic form and certain traits, epidemic O1 strains can be 
further differentiated into three serotypes, namely Inaba, Ogawa and Hikojima. The 3 
serotypes have been designated by the antigenic formulas AB (Inaba), AC (Ogawa) and 
ABC (Hikojima) respectively; with the A antigen common to all serotypes.  
 
1.5.3 Biotype 
Vibrio cholerae of the O1 serotype can be further classified into El Tor and Classical 
biotypes. They are distinguished by their hemolytic activity, agglutination reaction with 
erythrocytes, and Polymyxin B resistance.  
 
The Classical biotype was responsible for the pandemics from 1817 till 1923, spread from 
the Indian subcontinent to most other parts of the world. The seventh and ongoing pandemic 
which began in 1961 however, is predominated by the El Tor biotype. This biotype largely 
replaced the Classical biotype in India and other parts of the world.  
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1.6 CTXΦ Phage 
Cholera toxin or CT is encoded by the ctx operon carried by the CTXΦ bacteriophage. Not 
all Vibrio cholerae strains are toxigenic and can produce this toxin. A subset of V. cholerae 
acquired these toxin genes by means of bacteriophage infection or horizontal gene transfer 
(Davis and Waldor, 2003). 
 
Toxigenic V. cholerae O1 El Tor and O139 typically demonstrate possession of multiple 
CTX prophages that are inserted site-specifically near the terminus of ChrI, the larger of the 
two Vibrio chromosomes (Heidelberg et al., 2000, Das et al., 1993, Ehara et al., 1997). 
Hence, in these strains, it is possible to observe multiple ctx operons and reinfection by the 
bacteriophage. The O1 Classical biotype shows immunity to reinfection of the phage when 
an existing phage is present. Therefore, O1 Classical strains have only one copy of the ctx 
operon (Kimsey and Waldor, 1998).  
 
Contemporary toxigenic V. cholerae also contain the CTXΦ related element RS1. RS1 is a 
filamentous phage that is not autonomously transmissible but is instead a ‘satellite’ phage of 
CTXΦ. It is inserted adjacent to their CTX prophages and depends on the CTXΦ coat and 
secretion proteins for packaging. Both CTXΦ and RS1 have identical sequences at the 5’ 
ends.  They encode proteins used for replication, intergration and regulation of gene 
expression. The remaining genes in CTXΦ encode for proteins that are needed for packaging 
and secretion (pIIICTX, ace and zot) and CT, which is not involved in virion formation (Davis 
et al., 2002)  
 
CTXΦ is more dependent on host-encoded proteins compared to the prototypical Ff 
filamentous coliphages it is similar to. Studies have shown that chromosomal gene products 
facilitate the integration and secretion of this phage. The genome of the CTXΦ does not 
contain a sequence similar to any known integrase. Instead, chromosome-encoded 
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recombinases XerC and XerD are required for its integration (Huber and Waldor, 2002). 
CTXΦ relies also upon a chromosome-encoded secretin, EpsD for its secretion. Interestingly, 
the Eps system also mediates release of cholera toxin (Sandkvist et al., 1997, Sandkvist et al., 
1993). The secretion of the phage by the host cell allows for the simultaneous vertical and 
horizontal transmission of CTXΦ. Thus, CTXΦ can simultaneously be transferred to a new 
host cell and retained within the genome of the old host.  
 
1.7 Toxins & Proteins 
In the ctx operon, there are five identified genes, pIIICTX (formerly called orfU), ace, zot, 
ctxA and ctxB. All these genes, except pIIICTX, are involved in or assist in fluid secretion.  
 
The gene pIIICTX was formerly referred to as an open reading frame with unknown function. 
Heilpern et. al. hypothesized and found that the protein functioned in a similar manner to 
that of the coliphage fd protein pIII (Heilpern and Waldor, 2003). The protein was found to 
mediate CTXΦ infection as well as played a role in CTXΦ assembly and release. 
 
Another potential enterotoxin produced by V. cholerae that has been identified is the 
accessory cholera enterotoxin (Trucksis et al., 1993). It has been demonstrated that the 11.3-
kDa product can cause fluid accumulation in adult rabbit ileal loops and in a sealed infant 
mouse model (Trucksis et al., 1993). Culture supernatants from constructs devoid of CT and 
Zot but containing the ace gene demonstrated a significant increase in short circuit current 
secondary to an increase in potential difference in Ussing preparations. This toxin is 
suspected to be the cause behind the mild to moderate diarrhea experienced by volunteers of 
vaccine candidates, JBK70 and CVD101. It has also been found that the mechanism of 
secretion by this toxin involves Ca2+ as a second messenger and it stimulates a novel Ca2+-
dependent synergy (Trucksis et al., 1993). 
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The zonula occludens toxin coded by zot, is a 44.8kDa protein that is cleaved and gives rise 
to a 33kDa N-terminal fragment and a 12 kDa or smaller C-terminal fragment. This toxin 
activates a complex intracellular sequence of events that regulate tight junction permeability 
of the small intestinal mucosa (Fasano et al., 1995). The increase in the permeability of the 
mucosa enables the bacteria to colonize more easily and also enhances the influx of cholera 
toxin into intestinal cells. It has been observed that purified Zot primarily binds to a cell 
receptor, rearranges the cell cytoskeleton(Fasano et al., 1995), and induces secretion in the 
small intestines in rabbit models (Fasano et al., 1997).  It is also suggested that zot is 
involved in the CTXΦ morphogenesis together with pIIICTX, to assemble the filamentous 
phage at the bacterial envelope (Uzzau et al., 1999).  
 
The cholera toxin (CT) itself however is the main cause of the characteristic rice watery stool 
diarrhea of cholera. CT is a hexameric protein that consists of 5 B subunits (coded by ctxB) 
and 1 A subsunit (coded by ctxA).  
 
The pentamer B subunit contains the GM1 ganglioside receptor binding site and is 
responsible for the binding properties of the protein. When the toxin is secreted in the small 
intestines, the B subunit will bind to the GM1 ganglioside, a glycolipid which is practically 
ubiquitous in eukaryotic cell membranes. The binding of the toxin will then lead to the 
release of the A subunit into the intestinal cells.  
 
The A subunit is an ADP-ribosyltransferase, an enzyme responsible for the toxicity of the 
molecule and the diarrheal effect characteristic of cholera. The A subunit will then cleave 
into two peptides, A1 and A2. The two proteolytically cleaved proteins are still linked by 
disulphide bonds before internalization (Gill and Rappaport, 1979). The A1 peptide will 
enzymatically transfer ADP-ribose from nicotinamide adenine dinucleotide (NAD) to a 
target protein. The target protein is the guanosine 5’-triphosphate (GTP)-binding regulatory 
protein associated with membrane bound adenylate cyclase. It ‘locks’ adenylate cyclase in its 
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‘on mode’ and this leads to excessive production of cyclic adenosine 51-monophosphate 
(cAMP). The accumulation of cAMP in the intestinal cells will cause hypersecretion of 
chloride, bicarbonate and finally, water into the intestinal lumen. 
 
As mentioned, the A subunit is an enzyme. Thus, it has an active site with a specific 
configuration (Fontana et al., 1995, Jobling and Holmes, 2001). This configuration is 
produced through the interaction of certain amino acids through hydrogen bonds and 
disulphide bonds. If these bonds are changed, certain configurations may be altered. These 
alterations are particularly important in the inactivation of enzymes. This is because enzymes 
have specific sites, known as active sites, that are used to bind to specific sites of particular 
substrates. Once the active sites have been altered, the enzymes cannot bind to their 
substrates and therefore cannot perform their intended functions. By altering the active site 
of the A subunit, the molecule is unable to function enzymatically and its toxigenicity is 
addressed (Fontana et al., 1995). 
 
1.8 VCUSM2 
VCUSM2 is an ALA (δ-aminolevulinic acid) auxotrophic O139 strain in which a frameshift 
mutation has been carried out on the hemA gene. The gene encodes for glutamyl-tRNA 
reductase, an important enzyme in the C5 pathway of ALA biosynthesis. Studies have shown 
that VCUSM2 is able to colonize and induces good immune response in animal models. 
Rabbit ileal loop ligation experiments show that VCUSM2 is less reactogenic than its 
parental wildtype O139 strain. However, slight fluid accumulation was still observed at 
higher doses of CFU (Ravichandran et al., 2006). 
 
Although studies have shown that VCUSM2 is less toxigenic than the parental wildtype 
O139 strain, it is still essentially toxigenic as it possesses the complete ctxAB gene. 
VCUSM2 has been identified to possess double copies of ctx operon, arranged in tandem 
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(unpublished data). This data was acquired by digesting the purified genomic DNA with 
specific enzymes and performing a Southern Blot with specially designed probes. The 
experiments were performed and analyzed by researchers in Cuba. The double copies of ctx 
operon in VCUSM2 are fully functional and cause significant amounts of fluid accumulation 
as well as hemorrhaging in rabbit ileal loop model experiments (Ravichandran et al., 2006).  
 
1.9 Objectives 
It is the objective of this study to genetically manipulate VCUSM2 that its toxigenicity may 
be reduced. The study aims to delete the ace and zot genes in the operon by means of inverse 
PCR because these genes can contribute to mild diarrhea. Also, the study aims to mutate the 
ctxA gene at two specific sites so that two amino acids involved in the formation of the 
active site of the enzyme will be changed, rendering it non-functional. The target amino 
acids are the 7th and 112th amino acid of the A subunit. The 7th is arginine and has been 
substituted for lysine (R7K). The 112th is glutamate and was substituted with glutamine 
(E112Q). 
 
The obtained ctx operon mutant Vibrio cholerae was then subjected to evaluation in areas of 
CT production, reactogenicity and colonization abilities.  
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Chapter 2: Materials and Methods 
2.1 Experimental overview 
 
Figure 1: Experimental overview 
 
 
 
 
Primer design 
Cloning of ctx operon into pTZ57R 
Deletion of ace & zot by inverse PCR 
DNA sequencing & confirmation of mutation 
Insertion of aphA gene at FseI site 
Truncate aphA gene by inverse PCR 
Conjugation, sucrose selection & screening for mutants 
CT ELISA Animal studies 
Rabbit ileal loop Infant mouse colonization 
Restrict with SacI & SmaI and subclone into pWM91 
Mutation of 7th and 112th amino acid codon by 
site directed mutagenesis 
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2.2 Reagents, chemicals, kits 
 
2.2.1 Culture media 
2.2.1.1 Luria Bertani (LB) agar 
Tryptone ………………………………… 15 g 
Yeast extract …………………………….. 5 g 
Sodium Chloride ………………………… 10 g  
Agar ……………………………………… 15 g 
Distilled water …………………………… to 1L 
 
The ingredients were dissolved in 750 ml of distilled water. The pH was adjusted to 7.2 
using 1M NaOH. The volume was made up to 1 L with distilled water and the medium was 
autoclaved at 121oC for 15 minute. The medium was allowed to cool at around 45oC and 
poured aseptically into the plastic Petri plates. The Petri plates were incubated at 37oC for 12 
h and visually inspected for the presence of any bacterial/ fungal contamination. The plates 
were stored at 4oC for not more than 30 days.  
 
2.2.1.2 Luria Bertani (LB) broth 
Tryptone ………………………………… 15 g 
Yeast extract …………………………….. 5 g 
Sodium Chloride ………………………… 10 g  
Distilled water …………………………… to 1L 
 
The ingredients were dissolved in 750 ml of distilled water and the pH was adjusted to 7.2 
using 1M NaOH. The volume was made up to 1 litre with distilled water. The medium was 
distributed in 10 ml aliquots in universal bottles and autoclaved at 121oC for 15 minutes. The 
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medium was incubated at 37oC for 12 h and visually inspected for the presence of any 
bacterial/ fungal contamination. The medium was stored at room temperature for not more 
than 30 days. 
 
2.2.1.3 Modified LB agar without NaCl and with 10% sucrose 
Tryptone ………………………………… 15 g 
Yeast extract …………………………….. 5 g 
Agar ……………………………………… 15 g 
Distilled water …………………………… to 500 ml 
 
The ingredients were dissolved in 200 ml of distilled water and the pH was adjusted to 7.2 
using 1M NaOH. The volume was made up to 250 ml with distilled water and the medium 
was autoclaved at 121oC for 15 minutes. The medium was allowed to cool to around 55oC 
and added with 250 ml of sterile, warm (about 50oC) 20% sucrose solution.  
2.2.1.4 Modified LB broth without NaCl and with 10% sucrose 
Tryptone ………………………………… 15 g 
Yeast extract …………………………….. 5 g 
Distilled water …………………………... to 500 ml 
 
The ingredients were dissolved in 200 ml of distilled water and the pH was adjusted to 7.2 
using 1M NaOH and the volume was made up to 250 ml with distilled water. The medium 
was distributed in 5 ml aliquots in universal bottles and autoclaved at 121oC for 15 minutes. 
Each bottle was then added with 5 ml of 20% sterile sucrose solution. The medium was 
incubated at 37oC for 12 h and visually inspected for the presence of any bacterial/ fungal 
contamination.  
 15
2.2.1.5 TCBS Agar 
Dehydrated TCBS Powder ………………. 80 g 
Distilled water …………………………… to 1L 
 
TCBS agar was dissolved in 1L of autoclaved distilled water and the medium was brought to 
a boil on a Bunsen burner. The medium was allowed to cool to 50oC and poured in Petri 
plates. The plates were incubated at 37oC for 12 h and visually inspected for the presence of 
any bacterial or fungal growth. The plates were stored at 4oC for not more than 30 days. 
 
2.2.1.6 Addition of antibiotics/ supplements to the agar based media 
The medium was allowed to cool to about 45oC and sterile stock solutions of 
antibiotics or other supplements were added aseptically to the culture medium. The 
final concentration of various antibiotics and other supplements used in the present 
study were Ampicillin (100 µg /ml); Polymyxin (0.75 µg /ml or 450 unit/ ml); 
Kanamycin (50 µg /ml); ALA (80 µg /ml). For medium used in selection of 
merodiploids, ampicillin concentration was quadrupled. The medium was swirled to 
mix the contents well and poured aseptically into the plastic Petri plates. The plates 
were incubated at 37oC for 12 h and visually inspected for the presence of any 
bacterial or fungal growth. The plates were stored at 4oC for not more than 30 days. 
 
 
 
 
 
 
 
 
 
 
 
 
 16
2.2.2 General buffers, stock solutions, antibiotics 
Following are the general buffers, stock solutions and antibiotics used throughout this study.  
2.2.2.1 δ-Aminolevulinic Acid 40 mg /ml 
δ-Aminolevulinic acid …………………… 400 mg 
Distilled water …………………………… up to 10 ml 
 
δ-Aminolevulinic acid salt was dissolved in autoclaved distilled water and filter sterilized by 
passing through 0.22 µm nitrocellulose membrane. The solution was stored in 1 ml aliquots 
in sterile 1.5 ml micro-centrifuge tubes at -20oC. 
 
2.2.2.2 Ampicillin 100 mg/ml 
Ampicillin ………….. …………………… 500 mg 
Distilled water …………………………… up to 5 ml 
Salt was dissolved in autoclaved distilled water and filter sterilized by passing through 0.22 
µm nitrocellulose membrane. The ampicillin solution was stored in 1 ml aliquots in sterile 
1.5 ml micro-centrifuge tubes at -20oC. 
 
2.2.2.3 Calcium chloride 100 mM 
Calcium chloride dihydrate ……………… 14.7 g 
Distilled water …………………………… up to 1 L 
 
Calcium chloride was dissolved in autoclaved distilled water and filter sterilized by passing 
through a 0.22 µm nitrocellulose membrane. The solution was stored at 4oC. 
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2.2.2.4 Carbonate buffer 60 mM pH 9.6  
Sodium bicarbonate 60 mM ……………… 100 ml 
Sodium carbonate 60 mM ………………… 20 ml 
 
Sodium carbonate and sodium bicarbonate solutions were mixed, filter sterilized by passing 
through a 0.22 µm nitrocellulose membrane, and stored at room temperature (21-23oC) for 
not more than 30 days.  
 
2.2.2.5 Cholera toxin (0.5 µg /ml) 
Cholera toxin (1 mg /ml) …………………. 5 µl 
Carbonate buffer 60 mM (pH 9.6) ………… to 10 ml 
 
This solution was used immediately as a control in ELISA. 
 
2.2.2.6 Ethanol 70%  
Absolute ethanol ………………………….. 700 ml 
Distilled water ……………………………. 300 ml 
 
The solution was stored at room temperature. 
 
2.2.2.7 EDTA 0.5 M 
EDTA disodium dihydrate ……………….. 186.1 g 
Distilled water …………………. ………... up to 1L 
 
EDTA was added into distilled water and the pH was adjusted to 8.0 with NaOH pellets. The 
volume was made up to 1L and the solution was stored at room temperature. 
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2.2.2.8 Ethidium bromide 10 mg /ml 
Ethidium bromide tablet………………… 100 mg 
Distilled water …………………............... 10 ml 
 
The tablet was dissolved and kept in an opaque bottle. The solution was stored at room 
temperature. 
2.2.2.9 Gel loading dye 6X 
Orange G ………………………………… 200 mg 
Glycerol .………………………………… 60 ml 
EDTA 0.5M.…………………………….. 12 ml 
Distilled water ………………………….. up to 100 ml 
 
EDTA solution, glycerol and Orange G powder were added together and mixed thoroughly. 
Distilled water was added to the solution to make it 100ml. The solution was filter sterilized 
by passing through 0.22 µm nitrocellulose membrane and stored at -20oC. 
 
2.2.2.10 Glycerol 80% 
Glycerol ………………………………..  80 ml 
Distilled water ………………………… 20 ml 
 
Glycerol was mixed with autoclaved distilled water and sterilized by autoclaving at 121oC 
for 15 minutes. The solution was stored at room temperature. 
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2.2.2.11 Hydrochloric Acid 1N  
Hydrochloric acid (11.6 N) ……………… 8.62 ml 
Distilled water …………………………… 91.3 ml 
 
The solution was stored at room temperature. 
2.2.2.12 Kanamycin sulfate 50 mg /ml  
Kanamycin sulfate ……………………….. 500 mg 
Distilled water …………………………… 10 ml 
 
The solution was filter sterilized by passing through a 0.22 µm nitrocellulose membrane. The 
solution was stored in 1 ml aliquots at -20oC.  
 
2.2.2.13 Magnesium chloride 100 mM  
Magnesium chloride hexahydrate ………..……..20.33 g 
Distilled water…………………………………..up to 100 ml 
 
Magnesium chloride was dissolved in autoclaved distilled water and filter sterilized by 
passing through 0.22 µm nitrocellulose membrane. The solution was stored at 4oC. 
 
2.2.2.14 Normal saline (0.9% NaCl) 
Sodium chloride …………………………. 9 g 
Distilled water …………………………… up to 1 L 
 
Sodium chloride was dissolved in distilled water and sterilized by autoclaving at 121oC for 
15 minutes. The solution was stored at room temperature. 
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2.2.2.15 Phosphate Buffered Saline (PBS) 10 X  
Sodium chloride …………………………. 80 g 
Potassium chloride ………………………. 2 g 
Sodium phosphate dibasic heptahydrate … 14.4 g 
Potassium phosphate monobasic anhydrous 2.4 g 
Distilled water ………………………….up to 1L 
 
The salts were dissolved in distilled water and the pH was adjusted to 7.4 using 1N HCl/ 1M 
NaOH. The solution was sterilized by autoclaving at 121oC for 15 minutes and stored at 
room temperature. 
 
2.2.2.16 Phosphate Buffered Saline-Tween 20  
Phosphate buffered saline 10X …………... 100 ml 
Tween 20 ………………………………… 0.5 ml 
Distilled water …………………………… 900 ml 
 
The solution was stored at room temperature. 
 
2.2.2.17 Polymyxin B sulfate 0.75 mg /ml (4500 units) 
Polymyxin B sulfate (6000 units/ mg) ….... 7.5 mg 
Distilled water ………………………….... 10 ml 
 
Polymyxin B was dissolved in autoclaved distilled water and filter sterilized by passing 
through 0.22 µm nitrocellulose membrane. The solution was stored in 1 ml aliquots at -20oC.  
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2.2.2.18 Sodium bicarbonate 60 mM  
Sodium bicarbonate ………………….….. 5.04 g 
Distilled water …………………………… up to 1 L 
 
Sodium bicarbonate was dissolved in autoclaved distilled water and filter sterilized. The 
solution was stored at room temperature.  
 
2.2.2.19 Sodium carbonate 60 mM  
Sodium carbonate ………………….…….. 6.36 g 
Distilled water …………………………… up to 1 L 
 
Sodium carbonate was dissolved in autoclaved distilled water and filter sterilized. The 
solution was stored at room temperature.  
2.2.2.20 Sodium hydroxide 10M  
Sodium hydroxide ………………….……. 40 g 
Distilled water …………………………… up to 100ml 
 
Sodium hydroxide was dissolved in distilled water and stored at room temperature.  
 
2.2.2.21 Sodium hydroxide 1M  
Sodium hydroxide 10 M …..……….……. 10 ml 
Distilled water …………………………… 90 ml 
 
The solution was stored at room temperature.  
 
 22
2.2.2.22 Skimmed milk 5%  
Skimmed milk …………………………… 5 g 
Distilled water …………………………… up to 100 ml 
 
When used in freeze drying of bacterial stocks, the solution was steam autoclaved and stored 
at -20oC. When used as blocking agent in ELISA, the solution was prepared fresh and used 
immediately.  
2.2.2.23 Tris Acetic Acid EDTA (TAE) 50X  
Tris base …………………………………. 242 g 
Acetic acid glacial ……………………….. 57.1 ml 
EDTA (0.5 M) …………………………… 100 ml 
Distilled water …………………………… up to 1L 
 
The solution was sterilized by autoclaving at 121oC for 15 minutes and stored at room 
temperature. 
 
2.2.2.24 Tris Acetic Acid EDTA (TAE) 1X  
TAE (50X) ……………………………….. 20 ml 
Distilled water …………………………… up to 1L 
The solution was store at room temperature. 
 
2.2.2.25 TypeIII Ganglioside (10 µg /ml) 
TypeIII ganglioside (10 mg /ml) ………… 10 µl 
Carbonate buffer 60 mM (pH 9.6) ..……… up to 10 ml 
 
This solution was used immediately to coat the ELISA plates. 
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2.2.3 Bacterial species and strains 
Following is a list of bacterial strains that have been used throughout this study. 
 
2.2.3.1 E. coli BW 20767- λ pir  
(RP4 2tet: mu-1kan::Tn7integrant leu 63:: rec A1 cre(510 hsdR17 end A1 Zbf-5 uid)(∆MluI): 
pir thi was gifted from Dr. Copass of Harvard Medical School, Boston, USA. 
 
2.2.3.2 E .coli TOP10  
(F-merA ∆(mrv hsdRMS mcrBC)φ80lacZ∆M15 ∆lac X74 deOR recA1araD139 ∆(ara-
leu)7697 galU galKrpsL(strR ) endA1 nupG) was obtained from Invitrogen Corp. USA 
 
2.2.3.3 V. cholerae O139 Bengal  
Isolated from a patient in Hospital Universiti Sains Malaysia, Kubang Kerian, 16150, 
Kelantan, Malaysia. 
 
2.2.3.4 VCUSM2  
This strain is a hemA mutant, derived from VCUSM1 by removing Kanamycin gene cassette 
from hemA gene. (Ravichandran et al., 2006) 
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2.2.4 Plasmids 
Following is a list of plasmid that have been purchased or procured from other research labs 
to be used in the present study. 
 
2.2.4.1 pTZ57R  
(CAP protein binding site, mRNA (LacZ), lac repressor (LacI) binding site, f1 packaging 
signal) was obtained from Fermentas.(Mead et al., 1986). The plasmid map can be found in 
Appendix A. 
 
2.2.4.2 pWM91 
(f1(+) ori lacZα of pBluescript II (SK+) unique polylinker sites:ApaI,BamHI,NotI,SacI, 
SmaI,SpeI and XhoI SacB SucR AmpR) was gifted by Dr. Copass of Harvard Medical School, 
Boston, USA. (Metcalf et al., 1996) 
 
2.2.5 Animals 
BALB/c albino mice and New Zealand white rabbits have been used throughout this study. 
All animals were obtained from Rumah Haiwan, Kampus Kesihatan, Universiti Sains 
Malaysia, 16150 Kubang Kerian, Kelantan. 
 
